We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Scrutiny of Generic Drugmaker Inspections Tops OIG Agenda
Scrutiny of Generic Drugmaker Inspections Tops OIG Agenda
The HHS Office of Inspector General (OIG) this year plans to analyze the findings from FDA inspections of generic drugmakers’ facilities to determine the effectiveness of inspections on ensuring the quality of generic medicines.